Search research articles
Contact Us
Filters
Showing results (71-80 of 176) with videos related to
Page
of 18
Sort By:
Cancer Treatment Reviews
|
October 9, 2022
Response to "Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias"
Guillermo Villacampa, Alberto Hernando-Calvo, Roger Berché, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 19, 2018
A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations
David Tamborero, Carlota Rubio-Perez, Ferran Muiños, et al.
Frontiers in Immunology
|
November 7, 2025
Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies
Greta Catani, Daniel Morchón-Araujo, Oriol Mirallas, et al.
ESMO Open
|
April 10, 2019
Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer
Victor Rodriguez-Freixinos, Fiorella Ruiz-Pace, Lorena Fariñas-Madrid, et al.
Cancers
|
March 6, 2021
Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy
Cristina Saura, Olga Sánchez, Sandra Martínez, et al.
Therapeutic Advances in Medical Oncology
|
August 13, 2020
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer
Giulia Martini, Rodrigo Dienstmann, Javier Ros, et al.
Journal of Comparative Effectiveness Research
|
April 24, 2026
Maximizing the impact of real-world evidence on cancer treatment: what do we need to achieve it?
Begoña Bermejo, Rodrigo Dienstmann, Meritxell Bellet, et al.
Virchows Archiv : an International Journal of Pathology
|
July 27, 2025
Comparison of immunohistochemical HER2 low detection in breast cancer using two antibodies assays in an interlaboratory study
Leonard Medeiros da Silva, Amanda Muniz Rodrigues, Daniel Bueno da Cunha, et al.
International Braz J Urol : Official Journal of the Brazilian Society of Urology
|
November 6, 2007
Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma
Daniel Herchenhorn, Rodrigo Dienstmann, Fabio A Peixoto, et al.
NPJ Precision Oncology
|
February 21, 2024
A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking?
Marta Ligero, Bente Gielen, Victor Navarro, et al.
Page
of 18
Search research articles
Search
Showing results (71-80 of 176) with videos related to
Sort By:
Page
of 18
Cancer Treatment Reviews
|
October 9, 2022
Response to "Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias"
Guillermo Villacampa, Alberto Hernando-Calvo, Roger Berché, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 19, 2018
A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations
David Tamborero, Carlota Rubio-Perez, Ferran Muiños, et al.
Frontiers in Immunology
|
November 7, 2025
Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies
Greta Catani, Daniel Morchón-Araujo, Oriol Mirallas, et al.
ESMO Open
|
April 10, 2019
Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer
Victor Rodriguez-Freixinos, Fiorella Ruiz-Pace, Lorena Fariñas-Madrid, et al.
Cancers
|
March 6, 2021
Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy
Cristina Saura, Olga Sánchez, Sandra Martínez, et al.
Therapeutic Advances in Medical Oncology
|
August 13, 2020
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer
Giulia Martini, Rodrigo Dienstmann, Javier Ros, et al.
Journal of Comparative Effectiveness Research
|
April 24, 2026
Maximizing the impact of real-world evidence on cancer treatment: what do we need to achieve it?
Begoña Bermejo, Rodrigo Dienstmann, Meritxell Bellet, et al.
Virchows Archiv : an International Journal of Pathology
|
July 27, 2025
Comparison of immunohistochemical HER2 low detection in breast cancer using two antibodies assays in an interlaboratory study
Leonard Medeiros da Silva, Amanda Muniz Rodrigues, Daniel Bueno da Cunha, et al.
International Braz J Urol : Official Journal of the Brazilian Society of Urology
|
November 6, 2007
Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma
Daniel Herchenhorn, Rodrigo Dienstmann, Fabio A Peixoto, et al.
NPJ Precision Oncology
|
February 21, 2024
A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking?
Marta Ligero, Bente Gielen, Victor Navarro, et al.
Page
of 18